1
|
Tao Z, Wang J, Wu H, Hu J, Li L, Zhou Y, Zheng Q, Zha L, Zha Z. Renal Clearable Mo-Based Polyoxometalate Nanoclusters: A Promising Radioprotectant against Ionizing Irradiation. ACS Appl Mater Interfaces 2023; 15:11474-11484. [PMID: 36702809 DOI: 10.1021/acsami.2c19282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
In response to diffused ionizing radiation damage throughout the body caused by nuclear leaks and inaccurate radiotherapy, radioprotectants with considerable free radical scavenging capacities, along with negligible adverse effects, are highly regarded. Herein, unlike being performed as toxic chemotherapeutic drug candidates, molybdenum-based polyoxometalate nanoclusters (Mo-POM NCs) were developed as a non-toxic potent radioprotectant with impressive free radical scavenging capacities for ionizing radiation protection. In comparison to the clinically used radioprotectant drug amifostine (AM), the as-prepared Mo-POM NCs exhibited effective shielding capacity by virtue of their antioxidant properties resulting from a valence shift of molybdenum ions, alleviating not only ionizing radiation-induced DNA damage but also disruption of the radiation-sensitive hematopoietic system. More encouragingly, without trouble with long-term retention in the body, ultra-small sized Mo-POM NCs prepared by the mimetic Folin-Ciocalteu assay can be removed from the body through the renal-urinary pathway and the hepato-enteral excretory system after completing the mission of radiation protection. This work broadened the biological applications of metal-based POM chemotherapeutic drugs to act as a neozoic radioprotectant.
Collapse
Affiliation(s)
- Zhenchao Tao
- The First Affiliated Hospital of USTC, School of Life Sciences and Medicine, University of Science and Technology of China, Hefei230031, P. R. China
- Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei230031, P. R. China
| | - Jingguo Wang
- School of Food and Biological Engineering, Hefei University of Technology, Hefei230009, P. R. China
| | - Haitao Wu
- School of Food and Biological Engineering, Hefei University of Technology, Hefei230009, P. R. China
| | - Jiaru Hu
- The First Affiliated Hospital of USTC, School of Life Sciences and Medicine, University of Science and Technology of China, Hefei230031, P. R. China
| | - Lu Li
- The First Affiliated Hospital of USTC, School of Life Sciences and Medicine, University of Science and Technology of China, Hefei230031, P. R. China
| | - Yuhang Zhou
- International Immunology Center, Anhui Agricultural University, Hefei230036, P. R. China
| | - Qi Zheng
- International Immunology Center, Anhui Agricultural University, Hefei230036, P. R. China
| | - Lisha Zha
- International Immunology Center, Anhui Agricultural University, Hefei230036, P. R. China
| | - Zhengbao Zha
- School of Food and Biological Engineering, Hefei University of Technology, Hefei230009, P. R. China
| |
Collapse
|